Ribozyme rescue of photoreceptor cells in P23H transgenic rats: Long-term survival and late-stage therapy
Open accessThe DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Abstract
Ribozyme-directed cleavage of mutant mRNAs appears to be a potentially effective therapeutic measure for dominantly inherited diseases. We previously demonstrated that two ribozymes targeted to the P23H mutation in rhodopsin slow photoreceptor degeneration in transgenic rats for up to 3 months of age when injected before significant degeneration at postnatal day (P) 15. We now have explored whether ribozyme rescue persists at older ages, and whether ribozymes are effective when injected later in the degeneration after significant photoreceptor cell loss. Recombinant adeno-associated virus (rAAV) vectors incorporating a proximal bovine rod opsin promoter were used to transfer either hairpin or hammerhead ribozyme genes to photoreceptors. For the study of long-term survival, rAAV was administered by subretinal injection at P15, and the rats were allowed to live up to 8 months of age. For the study of late-stage gene transfer, rAAV was administered at P30 or P45, when 40–45% of the photoreceptors already had degenerated. Eyes were examined functionally by the electroretinogram and structurally by morphometric analysis. When injected at P15, expression of either ribozyme markedly slowed the rate of photoreceptor degeneration for at least 8 months and resulted in significantly greater electroretinogram amplitudes at least up to P180. When injected at P30 or P45, virtually the same number of photoreceptors survived at P130 as when injected at P15. Ribozyme rescue appears to be a potentially effective, long-term therapy for autosomal dominant retinal degeneration and is highly effective even when the gene transfer is done after significant photoreceptor cell loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Relative tissue-specific expression of two gRNAs for CRISPR/Cas gene editing in myotubes was achieved by linking a muscle-specific MHCK7 promoter (pol II) with gRNA-linked self-cleaving ribozyme sequences derived of Hepatitis delta virus (HDV) and a Hammerhead (HH) sequence [134-137].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [136]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Retinitis pigmentosa. The Friedenwald Lecture.
Berson, E. L. (1993) · PubMed · Cited by 730
Photoreceptor degeneration in inherited retinal dystrophy delayed by basic fibroblast growth factor
Faktorovich, E. G., Steinberg, R. H., Yasumura, D., Matthes, M. T., & LaVail, M. M. (1990) · Nature · doi:10.1038/347083a0 · Cited by 710
Self-citationLewin, A. S., Drenser, K. A., Hauswirth, W. W., Nishikawa, S., Yasumura, D., Flannery, J. G., & LaVail, M. M. (1998) · Nature Medicine · doi:10.1038/nm0898-967 · Cited by 407
Self-citationEfficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus
Flannery, J. G., Zolotukhin, S., Vaquero, M. I., LaVail, M. M., Muzyczka, N., & Hauswirth, W. W. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6916 · Cited by 407
Self-citationInfluence of eye pigmentation and light deprivation on inherited retinal dystrophy in the rat
LaVail, M. M., & Battelle, B.-A. (1975) · Experimental Eye Research · doi:10.1016/0014-4835(75)90080-9 · Cited by 334
Self-citationPhotoreceptor cell rescue in retinal degeneration (rd) mice by in vivo gene therapy
Bennett, J., Tanabe, T., Sun, D., Zeng, Y., Kjeldbye, H., Gouras, P., & Maguire, A. M. (1996) · Nature Medicine · doi:10.1038/nm0696-649 · Cited by 316
The Structure, Function and Application of the Hammerhead Ribozyme
Birikh, K. R., Heaton, P. A., & Eckstein, F. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.t01-3-00001.x · Cited by 276
Bennett, J., Maguire, A. M., Cideciyan, A. V., Schnell, M., Glover, E., Anand, V., Aleman, T. S., Chirmule, N., Gupta, A. R., Huang, Y., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.17.9920 · Cited by 242
Unoki, K., & LaVail, M. M. (1994) · PubMed · Cited by 238
Self-citationBerson, E. L. (1991) · Archives of Ophthalmology · doi:10.1001/archopht.1991.01080010094039 · Cited by 231
Research works printed but not linked: 9
- Berson E L. Invest Ophthalmol Visual Sci. 1993;34:1659–1676. [PubMed] [Google Scholar]
- Gorin M B, Breitner J C S, De Jong P T V M, Hageman G S, Klaver C C W, Kuehn M H, Seddon J M. Mol Vis. 1999;5:29. [PubMed] [Google Scholar]
- Zack D J, Dean M, Molday R S, Nathans J, Redmond T M, Stone E M, Swaroop A, Valle D, Weber B H. Mol Vis. 1999;5:30. [PubMed] [Google Scholar]
- Akimoto M, Miyatake S, Kogishi J, Hangai M, Okazaki K, Takahashi J C, Saiki M, Iwaki M, Honda Y. Invest Ophthalmol Visual Sci. 1999;40:273–279. [PubMed] [Google Scholar]
- Pavco P A, Bouhana K S, Gallegos A M, Agrawal A, Blanchard K S, Grimm S L, Jensen K L, Andrews L E, Wincott F E, Pitot P A, et al. Clin Cancer Res. 2000;6:2094–2103. [PubMed] [Google Scholar]
- Drenser K A, Timmers A M, Hauswirth W W, Lewin A S. Invest Ophthalmol Visual Sci. 1998;39:681–689. [PubMed] [Google Scholar]
- Unoki K, LaVail M M. Invest Ophthalmol Visual Sci. 1994;35:907–915. [PubMed] [Google Scholar]
- Michon J J, Li Z L, Shioura N, Anderson R J, Tso M O M. Invest Ophthalmol Visual Sci. 1991;32:280–284. [PubMed] [Google Scholar]
- Bennett J, Duan D, Engelhardt J F, Maguire A M. Invest Ophthalmol Visual Sci. 1997;38:2857–2863. [PubMed] [Google Scholar]
Cited by
Items 101–200 of 202
Adeno-Associated Virus Mediated Gene Therapy for Retinal Degenerative Diseases
Stieger, K., Cronin, T., Bennett, J., & Rolling, F. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-370-7_8 · Cited by 35
Life History of Cones in the Rhodopsin-Mutant P23H-3 Rat: Evidence of Long-term Survival
Chrysostomou, V., Stone, J., & Valter, K. (2009) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-3003 · Cited by 34
Kraft, T. W., Allen, D. E., Petters, R. M., Hao, Y., Peng, Y. W., & Wong, F. (2005) · PubMed · Cited by 42
Weleber, R. G., Kurz, D. E., & Trzupek, K. M. (2003) · Ophthalmology Clinics of North America · doi:10.1016/s0896-1549(03)00072-5 · Cited by 33
“5 months, when 40% to 45% of the photoreceptors had degenerated [80,81].”
BackgroundExpectations in the treatment of retinal diseases: Neuroprotection
Osborne, N. N., Chidlow, G., Wood, J. P. M., Schmidt, K.-G., Casson, R. J., & Melena, J. (2001) · Current Eye Research · doi:10.1076/ceyr.22.5.321.5496 · Cited by 33
Emerging Gene Therapies for Retinal Degenerations
Cepko, C. L. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.0295-12.2012 · Cited by 33
“Vectors expressing such genes or knock-down cassettes have been developed and tested in animal models (LaVail et al., 2000; Schlichtenbrede et al., 2003; Pang et al., 2008; Chadderton et al., 2009; Raz-Prag et al., 2009; Palfi et al., 2010; Zou et al., 2011).”
Pinilla, I., Fernández‐Sánchez, L., Segura, F. J., Sánchez-Cano, A. I., Tamarit, J. M., Fuentes‐Broto, L., Eells, J. T., Lax, P., & Cuenca, N. (2015) · Experimental Eye Research · doi:10.1016/j.exer.2015.10.012 · Cited by 32
“In this study, we have employed the P23H transgenic rat, an animal that bears an autosomal dominant mutation in the rhodopsin gene (proline-tohistidine substitution) that causes photoreceptor dystrophy and death (LaVail et al., 2000; Lewin et al., 1998; Machida et al., 2000; Steinberg et al., 1996).”
BackgroundMethodAntisense Inhibition: Oligonucleotides, Ribozymes, and siRNAs
Zhang, Y. C., Taylor, M. M., Samson, W. K., & Phillips, M. I. (2004) · Humana Press eBooks · doi:10.1385/1-59259-854-4:011 · Cited by 31
“Ribozyme treatment has resulted in a halt of disease progression in various species including rat, dog, and now monkey (39,40).”
Potential Therapeutic Agents Against Retinal Diseases Caused by Aberrant Metabolism of Retinoids
Liu, X., Chen, J., Liu, Z., Li, J., Yao, K., & Wu, Y. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-18429 · Cited by 32
Mitra, R. N., Zheng, M., Weiss, E. R., & Han, Z. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.12.004 · Cited by 32
“This approach solves the problem of designing specific genetic therapeutic strategies for each mutation, which is impractical due to the lack of available mouse models, the time-consuming nature of the process and financial hurdles, before translating to adRP patients for therapeutic intervention [6,12].”
Pan, W.-H., Xin, P., Morrey, J. D., & Clawson, G. A. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2003.12.013 · Cited by 28
Gene Therapy for Genetic and Acquired Retinal Diseases
Chaum, E., & Hatton, M. P. (2002) · Survey of Ophthalmology · doi:10.1016/s0039-6257(02)00336-3 · Cited by 33
Effects of Subretinal Electrical Stimulation in Mer-KO Mice
Mocko, J. A., Kim, M., Faulkner, A. E., Cao, Y., Ciavatta, V. T., & Pardue, M. T. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-6750 · Cited by 25
The new landscape of retinal gene therapy
Ku, C. A., & Pennesi, M. E. (2020) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.31842 · Cited by 26
“…& Lewin, 2000; Trujillo, Myers, Fayazi, Butler, & Sullivan, 2019), although several proof of principle in vivo studies have been conducted (LaVail et al., 2000; Shaw et al., 2001). siRNA and shRNA are double-stranded RNA (dsRNA) molecules that are processed to single-stranded antisense…”
BackgroundSevere Retinal Degeneration Caused by a Novel Rhodopsin Mutation
Liu, H., Wang, M., Xia, C., Du, X., Flannery, J. G., Ridge, K. D., Beutler, B., & Gong, X. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-3585 · Cited by 24
Self-citationMutation-independent rescue of a novel mouse model of Retinitis Pigmentosa
Greenwald, D. L., Cashman, S. M., & Kumar‐Singh, R. (2012) · Gene Therapy · doi:10.1038/gt.2012.53 · Cited by 26
Gene therapy for retinal and choroidal diseases
Campochiaro, P. A. (2002) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2.5.537 · Cited by 23
“In this transgenic rat model, subretinal injection of AAV vectors encoding a ribozyme that targets mutant P23H rhodopsin slows photoreceptor degeneration [62,63].”
BackgroundGuanylate Cyclase-Activating Proteins and Retina Disease
Baehr, W., & Palczewski, K. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6191-2_4 · Cited by 25
“Viral gene transfer therapies of retinal diseases by an adeno-associated virus (AAV) vector have been very successful in several recessive animal models (Acland et al., 2001; Bennett et al., 1999; Bennett et al., 1998; Batten et al., 2005; LaVail et al., 2000; Haire et al., 2006; Williams et al., 2006).”
BackgroundConley, S. M., Nour, M., Fliesler, S. J., & Naash, M. I. (2007) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.07-0663 · Cited by 21
Taylor, M. M., & Samson, W. K. (2002) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00696.2001 · Cited by 22
“progression of the diseases in animal models (8, 9).”
BackgroundLiu, X., Feng, B. C., Vats, A., Tang, H. M., Seibel, W. L., Swaroop, M., Tawa, G. J., Zheng, W., Byrne, L. C., Schurdak, M. E., et al. (2020) · The FASEB Journal · doi:10.1096/fj.202000282r · Cited by 22
Shen, W., Lai, C., Lai, Y. K. Y., Zhang, D., Zaknich, T., Sutanto, E. N., Constable, I. J., & Rakoczy, P. E. (2003) · The Journal of Gene Medicine · doi:10.1002/jgm.375 · Cited by 21
Engineering Retina from Human Retinal Progenitors (Cell Lines)
Dutt, K., & Cao, Y. (2008) · Tissue Engineering Part A · doi:10.1089/ten.tea.2007.0358 · Cited by 20
A High-Throughput Drug Screening Strategy for Detecting Rhodopsin P23H Mutant Rescue and Degradation
Chen, Y., Tang, H., Seibel, W. L., Papoian, R., Li, X., Lambert, N. A., & Palczewski, K. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-16298 · Cited by 20
Recent Advancements in Gene Therapy for Hereditary Retinal Dystrophies
Öner, A. (2017) · Turkish Journal of Ophthalmology · doi:10.4274/tjo.41017 · Cited by 22
Gene Therapy for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa
Massengill, M. T., & Lewin, A. S. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000383 · Cited by 20
Self-citationProgress in Gene Therapy for Rhodopsin Autosomal Dominant Retinitis Pigmentosa
Sudharsan, R., & Beltran, W. A. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-27378-1_19 · Cited by 19
Applications of nucleic acid technology in the CNS
Trülzsch, B., & Wood, M. J. A. (2003) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02153.x · Cited by 17
Shahin, S., Xu, H., Lü, B., Mercado, A. T., Jones, M. K., Bakondi, B., & Wang, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040824 · Cited by 18
Bennett, J., Chung, D. C., & Maguire, A. M. (2012) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-386509-0.00013-2 · Cited by 20
“In addition, there has been success with strategies aimed at rescuing disease due to toxic gainof-function mutations (Chadderton et al., 2009; LaVail et al., 2000; Lewin et al., 1998; Millington-Ward et al., 2011; Mussolino et al., 2011; O’Reilly et al., 2007; Palfi et al., 2006; Tam et al., 2008, 2010).”
BackgroundAbsence of Functional and Structural Abnormalities Associated with Expression of EGFP in the Retina
Nour, M., Quiambao, A. B., Al-Ubaidi, M. R., & Naash, M. I. (2004) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.03-0663 · Cited by 16
Kolniak, T. A., & Sullivan, J. M. (2011) · Experimental Eye Research · doi:10.1016/j.exer.2011.01.004 · Cited by 15
“…agents hold vast potential as candidate therapeutics for a multitude of diseases, including those of the eye (Millington-Ward et al., 1997; Lewin et al., 1998; LaVail et al., 2000; Farrar et al., 2002; Gorbatyuk et al., 2007; O'Reilly et al., 2007; Sullivan et al., 2008; Abdelmaksoud et al., 2009).”
BackgroundAnti-clarin-1 AAV-delivered ribozyme induced apoptosis in the mouse cochlea
Aarnisalo, A. A., Pietola, L., Joensuu, J., Isosomppi, J., Aarnisalo, P., Dinculescu, A., Lewin, A. S., Flannery, J. G., Hauswirth, W. W., Sankila, E., et al. (2007) · Hearing Research · doi:10.1016/j.heares.2007.03.004 · Cited by 14
Self-citationKumar, R., & Dutt, K. (2006) · Tissue Engineering · doi:10.1089/ten.2006.12.141 · Cited by 15
AAV vectors for RNA-based modulation of gene expression
Danos, O. (2008) · Gene Therapy · doi:10.1038/gt.2008.69 · Cited by 18
Abdelmaksoud, H. E., Yau, E. H., Zuker, M., & Sullivan, J. M. (2008) · Experimental Eye Research · doi:10.1016/j.exer.2008.11.018 · Cited by 15
“Can RNAi be used therapeutically without inducing cellular and organism toxicity.”
InfluentialRetinal Remodeling: Circuitry Revisions Triggered by Photoreceptor Degeneration
Marc, R. E., Jones, B. W., & Watt, C. B. (2006) · Springer eBooks · doi:10.1007/0-387-28190-8_3 · Cited by 16
“In dominant disease, stress triggered by transduction or protein processing defects (Hao et al., 2002, Illing et al., 2002) can potentially be ameliorated with molecular tools that promote photoreceptor survival (McGee Sanftner et al., 2001) or knock down expression of mutant genes ( LaVail et al., 2000, Lewin et al.,…”
BackgroundActivity of HDV ribozymes to trans-cleave HCV RNA
Yu, Y. (2002) · World Journal of Gastroenterology · doi:10.3748/wjg.v8.i4.694 · Cited by 13
“Hammerhead ribozymes and hairpin ribozymes have been tried widely to cleave many target RNAs, such as pathogenic microbes RNA[5-10], oncogene mRNA[11-15] and other kinds of pathogenity-associated functional mRNA[ 16-18 ].”
BackgroundGene therapies for inherited retinal disorders
Farrar, G. J., Millington‐Ward, S., Chadderton, N., Mansergh, F. C., & Palfi, A. (2014) · Visual Neuroscience · doi:10.1017/s0952523814000133 · Cited by 14
Jacobson, S. G., Boye, S. L., Alemán, T. S., Conlon, T. J., Zeiss, C. J., Román, A. J., Cideciyan, A. V., Schwartz, S., Komáromy, A. M., Doobrajh, M., et al. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.ft-230 · Cited by 12
Self-citationCRISPRi-Mediated Treatment of Dominant Rhodopsin-Associated Retinitis Pigmentosa
Burnight, E. R., Wiley, L. A., Mullin, N. K., Adur, M. K., Lang, M. J., Cranston, C. M., Jiao, C., Russell, S. R., Sohn, E. H., Han, I. C., et al. (2023) · The CRISPR Journal · doi:10.1089/crispr.2023.0039 · Cited by 14
“Several technologies, including hammerhead ribozy-mes (hhRzs), 5–9 RNA interference (RNAi), 10–13 and anti-sense oligonucleotides (ASOs), 14 each of which have specific advantages and disadvantages, have been evaluated as treatments for dominantly inherited disease.”
Zhu, Y., MISTRA, S., Nivison‐Smith, L., Acosta, M. L., Fletcher, E. L., & Kalloniatis, M. (2013) · Visual Neuroscience · doi:10.1017/s0952523813000047 · Cited by 11
“…and undergoes a gradual photoreceptor loss that is generally characteristic of human adRP, providing a model to investigate the cellular mechanisms that lead to photoreceptor loss and possible therapeutic strategies (LaVail et al., 2000 ; Machida et al., 2000 ; Aleman et al., 2001 ; Jensen, 2012 ).”
BackgroundHammerhead ribozymes for target validation
Goodchild, J. (2002) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.6.2.235 · Cited by 11
“Studies were performed either using transgenic animals obtained by microinjection of ribozyme-expressing plasmids into embryos [92,95,96,99,100], or by using adenoviral [28,30,91,94,98] or retroviral vectors [67] to express the ribozyme.”
BackgroundChang, A. Y. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2651-1_33 · Cited by 20
Sun, X., Chen, Y., Chen, Y., Cui, T., Han, J., Dai, M., Zhang, Y., Zhou, Q., & Li, W. (2024) · Human Gene Therapy · doi:10.1089/hum.2023.201 · Cited by 10
Gene Therapy in the Retinal Degeneration Slow Model of Retinitis Pigmentosa
Cai, X., Conley, S. M., & Naash, M. I. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-1399-9_70 · Cited by 12
“Ribozymes have been successfully used to treat rhodopsin-associated adRP: AAV-ribozyme delivered to rhodopsin rats carrying the P23H mutation significantly decreased P23H transgene mRNA level, significantly reduced photoreceptor loss, increased outer nuclear layer (ONL) thickness, and improved scotopic b-wave amplitud…”
BackgroundMethodTritz, R., Habita, C., Robbins, J. M., Gomez, G. G., & Kruse, C. A. (2005) · PubMed · Cited by 10
Wang, W., Guo, D.-Y., & Tao, Y. (2018) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2018.09.002 · Cited by 9
Nour, M., & Naash, M. I. (2003) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-0067-4_22 · Cited by 8
In vivo versus ex vivo CRISPR therapies for retinal dystrophy
Bakondi, B. (2016) · Expert Review of Ophthalmology · doi:10.1080/17469899.2016.1251316 · Cited by 8
“These investigators also showed the window of opportunity for photoreceptor rescue to not diminish with disease progression [14].”
BackgroundDu, W., Li, J., Tang, X., Yu, W., & Zhao, M. (2023) · Experimental Biology and Medicine · doi:10.1177/15353702231199069 · Cited by 9
Hearing impairment in the P23H-1 retinal degeneration rat model
Sotoca, J. V., Alvarado, J. C., Fuentes‐Santamaría, V., Martinez-Galan, J. R., & Caminos, E. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00297 · Cited by 7
“Transgenic rats have a proline-23 to histidine (pro23His) rhodopsin mutation (LaVail et al., 2000; Aleman et al., 2001).”
BackgroundVariables and Strategies in Development of Therapeutic Post-Transcriptional Gene Silencing Agents
Sullivan, J. M., Yau, E. H., Kolniak, T. A., Sheflin, L. G., Taggart, R. T., & Abdelmaksoud, H. E. (2011) · Journal of Ophthalmology · doi:10.1155/2011/531380 · Cited by 7
Gene, Oligonucleotide, and Ribozyme Therapy in the Eye
DAS, S. K., & Miller, K. (2003) · CRC Press eBooks · doi:10.1201/9780203912072.ch19 · Cited by 6
Shen, W., Lai, Y. K. Y., Lai, C., & Rakoczy, P. E. (2003) · Vision Research · doi:10.1016/j.visres.2003.09.032 · Cited by 7
RNA-Mediated Therapeutics: From Gene Inactivation to Clinical Application
Kalavrizioti, D., Vourekas, A., Stamatopoulou, V., Toumpeki, C., Giannouli, S., Stathopoulos, C., & Drainas, D. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606778194253 · Cited by 12
“In a very promising series of reports, anti-P23H ribozymes administered by adeno-associated vectors in a mouse retinitis model, markedly slowed the rate of photoreceptor degeneration, even when delivered at a late developmental stage [40,149].”
BackgroundMethodAdeno-associated virus (AAV) based gene therapy for eye diseases
Wang, S., Liu, P., Song, L., Lü, L., Zhang, W., & Ya-zhen, W. (2011) · Cell and Tissue Banking · doi:10.1007/s10561-011-9243-7 · Cited by 5
“For instance, in the cases with over-expression of mutated genes, AAV-delivered hairpin or hammerhead ribozymes to clear mutant mRNA transcripts of P23H, for example, have achieved some rescue results (Drenser et al. 1998; LaVail et al. 2000; Lewin et al. 1998).”
BackgroundGene Therapy for Mouse Models of ADRP
Gorbatyuk, M. S., Hauswirth, W. W., & Lewin, A. S. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-74904-4_11 · Cited by 5
“Mice and rats models have become extremely helpful for the study and the development of treatments for ADRP ( LaVail et al., 2000; Machida et al., 2000; Kijas et al., 2002).”
BackgroundSelf-citationChallenging Safety and Efficacy of Retinal Gene Therapies by Retinogenesis
Marrocco, E., Maritato, R., Botta, S., Esposito, M., & Surace, E. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115767 · Cited by 6
“Ribozymes [20], RNA interference [21,22], and antisense oligonucleotides degrade Rho mRNA transcript upon pairing [23].”
BackgroundMenon, R. P., Menon, M. R., Shiwen, X., Renzoni, E. A., Bou–Gharios, G., Black, C. M., & Abraham, D. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2006.01.011 · Cited by 5
Gene Therapy for Rhodopsin Mutations
Lewin, A. S., & Smith, W. C. (2022) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041283 · Cited by 7
Self-citationRobust expression of the TRPC1 channel associated with photoreceptor loss in the rat retina
Caminos, E., Murillo-Martínez, M., García-Belando, M., Cabanes-Sanchis, J. J., & Martinez-Galan, J. R. (2023) · Experimental Eye Research · doi:10.1016/j.exer.2023.109655 · Cited by 4
In vitro Analysis of Ribozyme-mediated Knockdown of an ADRP Associated Rhodopsin Mutation
Chakraborty, D., Whalen, P. O., Lewin, A. S., & Naash, M. I. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-74904-4_10 · Cited by 4
“The second approach is to block the synthesis of mutant proteins and increasing the ratio of wildtype vs mutant rhodopsin to delay the onset of retinal degeneration (Drenser et al., 1998; LaVail et al., 2000).”
BackgroundMethodInfluentialSelf-citationTherapeutic Applications of Ribozymes
Rossi, J. J. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-777-2_4 · Cited by 4
Dagnelie, G., Stronks, H. C., & Barry, M. P. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-398358-9.00069-0 · Cited by 3
Kinoshita, J., Hasan, N., Bell, B. A., & Peachey, N. S. (2019) · PubMed Central · Cited by 3
Ophthalmic transplantology: Posterior segment of the eye – Part II
Nita, M., Strzałka‐Mrozik, B., Grzybowski, A. E., Romaniuk, W., & Mazurek, U. M. (2012) · Medical Science Monitor · doi:10.12659/msm.882868 · Cited by 3
“No treatment has been proposed for atrophic maculopathy [9,10].”
Stammzellbasierte Therapieansätze für retinale Erkrankungen
Bartsch, U., Linke, S., & Petrowitz, B. (2005) · Der Ophthalmologe · doi:10.1007/s00347-005-1188-4 · Cited by 3
Gene Therapy for Retinal Disease
Bennett, J., & Maguire, A. M. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0737-9.00034-5 · Cited by 2
Dollfus, H., Perdomo-Trujillo, Y., & Pelletier, V. (2010) · Encyclopédie médico-chirurgicale. Ophtalmologie · doi:10.1016/s0246-0343(10)46621-6 · Cited by 2
Gene Therapy for Dominantly Inherited Retinal Degeneration
Farrar, G. J., Millington‐Ward, S., Palfi, A., Chadderton, N., & Kenna, P. F. (2014) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-3-662-45188-5_4 · Cited by 4
Rapid in vivo isolation of gene expression elements using an HSV amplicon system
Huang, C., & Brandt, C. R. (2003) · Journal of Virological Methods · doi:10.1016/s0166-0934(03)00183-6 · Cited by 2
Michalakis, S., Gerhardt, M.-J., Priglinger, C., & Priglinger, S. G. (2021) · Springer eBooks · doi:10.1007/978-3-319-90495-5_150-1 · Cited by 1
Photobiomodulation in inherited retinal degeneration
Gopalakrishnan, S. (2012) · UWM Digital Commons (University of Wisconsin–Milwaukee) · Cited by 1
Increased Light Sensitivity in Mice Expressing a T17M Mutant Human Rhodopsin Transgene
White, A. F., Hauswirth, W. W., Li, Q., & Lewin, A. S. (2006) · Investigative Ophthalmology & Visual Science · Cited by 1
Self-citationMichalakis, S., Gerhardt, M.-J., Priglinger, C., & Priglinger, S. G. (2022) · Springer eBooks · doi:10.1007/978-3-030-42634-7_150 · Cited by 1
Retinal Degenerations: Genetics, Mechanisms, and Therapies
MacDonald, I. M., Naash, M. I., & Ayyagari, R. (2011) · Journal of Ophthalmology · doi:10.1155/2011/764873 · Cited by 1
Molecular Genetics for the Pediatric Ophthalmologist
Bollinger, K. E., & Traboulsi, E. I. (2007) · Journal of Pediatric Ophthalmology & Strabismus · doi:10.3928/01913913-20070701-01 · Cited by 1
Gene Therapy for Childhood Onset Blindness
Bennett, J. (2003) · CRC Press eBooks · doi:10.1201/9780824758608.ch33 · Cited by 1
Viral vector-mediated RNA interference in the retina
Georgiadis, A. (2010) · UCL Discovery (University College London)
New Experimental Therapeutic Approaches for Degenerative Diseases of the Retina
Tombran‐Tink, J. (2021) · Routledge eBooks · doi:10.4324/9781003113423-23
EXPERIMENTAL AND CLINICAL OCULAR GENE THERAPY
Bemelmans, A., & Sahel, J. (2019) · WORLD SCIENTIFIC (EUROPE) eBooks · doi:10.1142/9781786346889_0025
Venkatesh, A. (2016) · eScholarship@UMassChan · doi:10.13028/m2nc7g
RNA interference therapy for the Spinocerebellar ataxias
Ramachandran, P. S. (2014) · doi:10.17077/etd.xa5w8n22
“Early gene knockdown strategies using ribozymes, RNA enzymes that cleave specific mRNA molecules, demonstrated delayed photoreceptor degeneration in a rat model of autosomal dominant retinitis pigmentosa (183, 184).”
BackgroundChader, G. J. (2008) · Elsevier eBooks · doi:10.1016/b978-012370585-3.50022-4
Dagnelie, G. (2007) · Elsevier eBooks · doi:10.1016/b978-012370615-7/50073-1
Falsini, B., Bush, R. A., & Sieving, P. A. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0737-9.00037-0 · Cited by 1
Nesbit, M. A., & Moore, T. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817876-8.00006-1
Dagnelie, G., Stronks, H. C., & Barry, M. P. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818422-6.00065-4
Gene Therapy for Childhood Onset Blindness
Canver, M. C., & Bennett, J. (2008) · CRC Press eBooks · doi:10.1201/9780849387999.ch43
New Experimental Therapeutic Approaches for Degenerative Diseases of the Retina
Tombran‐Tink, J. (2003) · CRC Press eBooks · doi:10.1201/9780203912072.ch18
Rossmiller, B. P., & Bagheri, M. (2023) · doi:10.14293/s2199-1006.1.sor-.ppbjpmo.v1
Rossmiller, B. P., & Bagheri, M. (2023) · doi:10.14293/s2199-1006.1.sor-.ppbjpmo.v2
Selective Assembly of TRPC Channels in the Rat Retina during Photoreceptor Degeneration
Caminos, E., López‐López, S., & Martinez-Galan, J. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137251
“The P23H line 1 (P23H-1) transgenic rats carry a common rhodopsin mutation (proline-to-histidine substitution), generating an experimental model of neurodegeneration with features of RP [1,2].”
BackgroundGenetics and Gene Therapy of the TGFBI Corneal Dystrophies
Kowalczyk, A. M., Nesbit, M. A., McLain, A., & Moore, T. (2024) · Springer eBooks · doi:10.1007/978-981-96-0131-8_10
Adaptive changes in the visual cortex after photoreceptor degeneration in retinitis pigmentosa.
Martinez-Galan, J. R., & Caminos, E. (2025) · PubMed · doi:10.14670/hh-18-891
Gene Therapy for Neovascular Retinopathies
Raisler, B. J., Berns, K. I., & Hauswirth, W. W. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-047-8_20
“In the longest-term rodent study to date, AAV-delivered ribozymes designed against P23H rod opsin gene (48), a common cause of human autosomal dominant RP, preserved photoreceptors for at least 8 mo in a transgenic rat model of P23H opsin RP ( 49 ,50).”
BackgroundSelf-citation
Metadata
- Authors
- LaVail, M. M., Yasumura, D., Matthes, M. T., Drenser, K. A., Flannery, J. G., Lewin, A. S., & Hauswirth, W. W.
- Affiliations
- University of California, San Francisco (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2000-09-26
- Volume
- 97
- Issue
- 21
- Pages
- 11488-11493
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC17227
- OpenAlex
- W2077508733
- Cited by
- 203
- References
- 38
- Citations by year
- 2025: 2 · 2024: 3 · 2023: 6 · 2022: 4 · 2021: 5 · 2020: 5 · 2019: 3 · 2018: 5 · 2017: 7 · 2016: 5 · 2015: 8 · 2014: 9 · 2013: 6 · 2012: 12
- FWCI
- 5.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- March of Dimes Foundation
- Foundation Fighting Blindness
- Research to Prevent Blindness (EY02162)
- Macula Vision Research Foundation
- National Institutes of Health (EY01919, EY02162)
- National Eye Institute (EY-06842, EY02162, P30EY002162, EY-01919, R01EY011596, R01EY001919, P30EY008571, F32EY006842, R01EY011123, R01EY006842, T32EY007132)
- National Institute of Neurological Disorders and Stroke (P01NS036302)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- retinitis pigmentosa, photoreceptor degeneration, adeno-associated virus vectors, hairpin ribozyme, hammerhead ribozyme, transgenic rats, electroretinogram, long-term survival
- MeSH terms
- Animals, Cell Survival, Photoreceptor Cells, Retinal Diseases, Genetic Therapy, RNA, Catalytic, Animals, Genetically Modified, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.